Aardvark Therapeutics Inc

AARD has broken below its consolidation neckline in Stage 3 distribution, with EMAs rolling over and rising volume confirming the bearish resolve. Medium-term bias is firmly bearish, anchored by a declining 200-day SMA and a double-top breakdown. Short-term conditions remain unfavourable for longs, so we sell now on this breakdown and look to re-engage only after potential pullbacks into former support zones.

• ↑Unique Prader-Willi niche; ARD-101 success could unlock unmet demand
• ↑$73.9M cash runway to late 2027; R&D spend cut to $10.5M
• ↓FDA’s full clinical hold halts ARD-101 HERO/OLE trials, delaying launch